In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biohaven Pharmaceutical Holding Co. Ltd.

www.biohavenpharma.com

Latest From Biohaven Pharmaceutical Holding Co. Ltd.

Newron Not Seeing Sarizotan STARS Yet

The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.

Rare Diseases Clinical Trials

Priority Review Vouchers Post Lower Average Approval Times Than Priority NMEs

US FDA’s priority review voucher program delivers for most sponsors, a Pink Sheet analysis finds; PRVs reliably produce faster approval than priority-reviewed new drugs overall.

Review Pathway Regulation

Lilly Expands Migraine Franchise With Reyvow Approval

Reyvow gives Lilly a second MOA in migraine, following the anti-CGRP biologic Emgality, and adds an acute therapy to the preventive agent approved in 2018.

Approvals Business Strategies

Biopharma Quarterly Dealmaking Statistics, Q2 2019

Biopharma companies raised $12.4bn in Q2, largely from follow-on public offerings. In the latest mega-merger of the year, AbbVie spent $63bn on Allergan and its established portfolio. Many of the higher-valued alliances focused on the area of protein degradation.

Market Intelligence Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Biohaven Pharmaceuticals
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Biohaven Pharmaceutical Holding Co. Ltd.
  • Senior Management
  • Vlad Coric, MD, CEO
    Jim Engelhart, CFO
    Robert Berman, MD, CMO
    John Tilton, Chief Commercial Officer
    Charlie Conway, PhD, CSO
    Elyse Stock, MD, Chief, Portfolio Strategy & Dev.
    Donnie McGrath, MD, Chief, Corp. Strategy & Bus. Dev.
    Kim Gentile, VP, Operations
  • Contact Info
  • Biohaven Pharmaceutical Holding Co. Ltd.
    Phone: (203) 404-0410
    234 Church St.
    New Haven, CT 06510
    USA
UsernamePublicRestriction

Register